Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

IV Stem Cell Therapy for Lyme Disease & Sjögren’s Syndrome: A Real Patient Story

Written by Dr. David Greene, MD, PhD, MBA on June 15, 2026

Table of Contents

For patients managing multiple chronic illnesses simultaneously, finding an effective path forward can feel overwhelming. When conditions like Sjögren’s syndrome, Lyme disease, and Rocky Mountain spotted fever overlap, the symptom burden — particularly persistent fatigue and cognitive impairment — can significantly diminish quality of life. Conventional medicine often addresses each condition separately, leaving patients without adequate relief from their combined effects.

This article shares the experience of one such patient treated at R3 Stem Cell, explains the conditions involved and why they are medically challenging, and examines what current research says about stem cell therapy as a potential approach for autoimmune and tick-borne diseases.

Understanding the Conditions: What Lori Was Dealing With

Lori was diagnosed in January 2015 with three simultaneous conditions:

Sjögren's syndrome — a chronic autoimmune disease in which the immune system attacks moisture-producing glands, causing dryness, fatigue, joint pain, and, in systemic cases, organ involvement

Lyme disease T— a tick-borne bacterial infection caused by Borrelia burgdorferi; when untreated or inadequately treated, it can progress to a persistent condition involving fatigue, neurological symptoms, and musculoskeletal pain. Patients seeking more background can review the complications of Lyme disease and how systemic effects can persist well beyond initial infection.

Rocky Mountain spotted fever (RMSF) — a potentially serious bacterial infection transmitted by ticks, caused by Rickettsia rickettsii, which can produce systemic inflammation and, in some patients, long-term health consequences

Why This Combination Is Particularly Challenging

Each of these conditions independently affects the immune system and energy regulation. Together, they create a compounding symptom profile. The most prominent symptoms Lori experienced were extreme fatigue and brain fog — cognitive difficulty sometimes described as mental cloudiness, difficulty concentrating, or slowed thinking.

These symptoms are notoriously difficult to treat through standard approaches because they often lack a single, identifiable mechanism to target. Understanding what makes the immune system attack itself helps clarify why conditions like Sjögren’s syndrome are so difficult to resolve through conventional treatment alone. As a result, many patients with complex autoimmune or post-infectious presentations explore regenerative medicine options.

The Treatment: IV Stem Cell Infusion at R3 Stem Cell

Several years after her diagnosis, Lori connected with Dr. David Greene, founder and CEO of R3 Stem Cell, initially through a volunteer role. Dr. Greene offered her an intravenous (IV) stem cell infusion as part of her care.

IV administration delivers stem cells — typically mesenchymal stem cells (MSCs) derived from sources such as umbilical cord tissue or bone marrow — directly into the bloodstream. This systemic delivery method allows cells to circulate throughout the body and migrate toward sites of inflammation, which makes it a commonly used approach for conditions that affect multiple organ systems or are not localized to a single region. For a foundational explanation of how stem cell therapy works at a cellular level, including how MSCs communicate with surrounding tissue, R3 Stem Cell provides a helpful overview.

What She Experienced: The Patient's Report

Lori describes her results clearly and without exaggeration:

Fatigue resolved — the extreme, debilitating tiredness that accompanied all three conditions improved substantially

Brain fog lifted — cognitive clarity returned, allowing her to function more normally day-to-day

Overall well-being improved — she describes a general sense of feeling better that she found difficult to fully put into words

Importantly, she reports that these benefits have been sustained over multiple years since the treatment, not just in the short term following the infusion. Her account echoes the experiences shared by others in the autoimmune disease community who have benefited from stem cell therapy, where durable symptom relief — rather than temporary suppression — is the meaningful benchmark.

What the Research Says

It is important to contextualize patient experiences within the current scientific evidence base.

Stem Cell Therapy and Sjögren's Syndrome

Sjögren’s syndrome is an autoimmune condition, and MSCs have well-documented immunomodulatory properties — meaning they can help regulate overactive immune responses rather than simply suppressing them globally. The effects of stem cells on the immune system have been studied across a range of autoimmune conditions, with MSC infusions shown to reduce disease activity markers in early clinical research. Some participants in published trials have reported improved gland function and systemic symptom relief, though trial sizes remain small and long-term data are still limited.

Stem Cell Therapy and Lyme Disease / Tick-Borne Illness

Research specifically targeting Lyme disease with stem cell therapy is in very early stages. There are no large-scale randomized controlled trials to date. The rationale for its use centers on the immune dysregulation and persistent inflammation that characterize post-treatment Lyme disease syndrome, rather than directly targeting the bacterial infection itself. R3 Stem Cell has published a dedicated resource on stem cell treatment for Lyme disease that outlines the current thinking behind this approach and the biological mechanisms involved. Some researchers hypothesize that MSCs’ ability to modulate inflammatory signaling may help reduce symptom burden in these patients, but this remains an area requiring more rigorous investigation.

Fatigue and Brain Fog Across Autoimmune Conditions

Fatigue and cognitive impairment are common across autoimmune and post-infectious conditions, and both have been cited as outcome measures in early stem cell studies for diseases like lupus and multiple sclerosis. Patients exploring whether their condition can benefit from a regenerative therapy will find that systemic conditions producing fatigue and neuroinflammation are among those most commonly evaluated in regenerative medicine consultations. While this does not constitute direct evidence for Lori’s specific diagnoses, it supports the biological plausibility that MSC therapy could address some of the shared underlying mechanisms driving her symptoms.

Important note: Stem cell therapy for Sjögren’s syndrome, Lyme disease, or Rocky Mountain spotted fever has not been approved by the FDA as a standard treatment. Patients should approach this as an emerging, investigational option and consult a qualified provider to evaluate suitability based on individual medical history.

Why Lasting Results Matter

One of the most clinically meaningful aspects of Lori’s account is the durability of her improvement over several years. In regenerative medicine, the question of how long benefits persist is central to evaluating whether a treatment offers genuine disease modification or only temporary relief.

MSCs are thought to exert their effects not by permanently engrafting into host tissue, but by releasing signaling molecules — including cytokines, growth factors, and exosomes — that modulate the immune environment and support tissue healing. A closer look at how exosomes play into regenerative therapy helps illustrate why these signaling mechanisms can produce effects that extend well beyond the initial treatment window. The longevity of these effects varies by individual and condition, and sustained improvement suggests a meaningful biological response rather than a temporary or placebo effect, though rigorous individual case assessment would be needed to confirm this.

Is IV Stem Cell Therapy Right for Complex Chronic Illness?

There is no universal answer. What works for one patient’s profile may not apply to another, particularly when multiple overlapping conditions are involved. Factors that influence candidacy for IV stem cell therapy include the specific conditions present, disease duration and severity, prior treatment history, and overall immune status.

Patients interested in exploring this approach are encouraged to:

Schedule a thorough consultation with a regenerative medicine specialist. Understanding how to choose the right stem cell therapy physician — including what qualifications and transparency to look for — is an important first step.

Ask specifically about the type of stem cells used, the source, and the administration protocol

Review any available published research relevant to their conditions

Understand that this is a developing field, and informed consent should include an honest discussion of both potential benefits and current evidence limitations

R3 Stem Cell operates more than 80 treatment centers across eight countries and takes a case-by-case approach to patient evaluation, helping individuals determine whether a regenerative therapy aligns with their health goals and medical history. For those ready to take the next step, choosing the right stem cell clinic requires asking the right questions about provider experience, product sourcing, and realistic outcome expectations.

FAQs

Can stem cell therapy treat Lyme disease directly?

No. Stem cell therapy does not target the Borrelia burgdorferi bacteria responsible for Lyme disease. Its potential value lies in addressing the immune dysregulation and chronic inflammation that can persist after infection, particularly in patients with post-treatment Lyme disease syndrome.

Is IV stem cell therapy safe for autoimmune conditions like Sjögren's syndrome?

Early clinical data suggest IV MSC therapy is generally well tolerated in autoimmune populations, with a favorable safety profile in published trials. That said, safety always depends on the individual patient’s health status, the source and quality of cells used, and the clinical setting. A qualified provider should assess suitability before treatment.

How long do results from IV stem cell therapy last?

This varies significantly between patients and conditions. Some patients, like Lori, report benefits lasting multiple years. Others may experience more modest or shorter-duration improvements. Long-term durability data across conditions remain an active area of research.

What type of stem cells are typically used for autoimmune conditions?

Mesenchymal stem cells (MSCs), often derived from umbilical cord tissue (Wharton’s jelly) or bone marrow, are most commonly used. They are preferred for autoimmune applications due to their anti-inflammatory and immunomodulatory properties.

Final Thoughts

Lori’s experience illustrates something clinically meaningful: for patients whose chronic, overlapping conditions have not responded adequately to conventional treatment, IV stem cell therapy represents a genuinely promising avenue worth serious consideration. Her sustained relief from fatigue and brain fog — symptoms that significantly impaired her daily life for years — reflects outcomes that align with the biological mechanisms researchers are actively studying in MSC therapy.

The science is still developing, and no one should approach stem cell therapy without informed, realistic expectations. But for the right patient, with the right evaluation and the right clinical team, regenerative medicine may offer what conventional approaches have not.

Patients living with Sjögren’s syndrome, Lyme disease, tick-borne illness, or other complex autoimmune conditions are encouraged to speak with a qualified specialist to explore whether IV stem cell therapy deserves a place in their care plan.

Contact Us

iPSCs are not the same as stem cell therapies currently in use. Mesenchymal stem cell (MSC) therapies — derived from umbilical cord tissue, bone marrow, or fat — are available now and work through anti-inflammatory signaling and immune modulation rather than direct tissue replacement.

It’s also worth understanding the difference between stem cell therapy and other regenerative approaches, and how regenerative medicine differs from traditional medicine.

R3 Stem Cell, operating across 80+ centers in eight countries, focuses on these established therapies while monitoring iPSC developments as the science matures. Learn more about what regenerative medicine is and the benefits of regenerative medicine.

Stem cell therapy for diabetes is not yet a standard of care in most countries and is generally considered investigational or complementary. Patients should review FDA regulations on cell therapies for context.

The shift in thinking began with a significant clinical study from Stanford University, published in Stroke in 2016. Researchers injected mesenchymal stem cells directly into the brains of chronic stroke patients through surgically drilled openings. The results were striking — patients who were years past their strokes showed measurable improvements in motor function, with no serious adverse events linked to the stem cells.

A follow-up phase 2b trial confirmed both the safety profile and the continued functional benefit.

The key finding was not just that patients improved — it was when they improved. These were patients well outside the traditional recovery window, which proved that the brain retains the capacity to respond to regenerative signals long after injury. To understand more about how stem cell therapy works at the biological level, it helps to look at the signaling and repair mechanisms that make these results possible.

Why Dr. Hector is "Passionate" About the Word "Natural"

DNA Mutations — The reprogramming process can introduce genetic mutations — either pre-existing or induced — that raise serious safety concerns before cells can be used in patients.

Consent alone is not sufficient. Donor mothers also undergo comprehensive medical screening, which typically includes:

What Does the Bioethics Community Say?